ADRb3 ELISA kit
- Known as:
- ADRb3 Enzyme-linked immunosorbent assay test reagent
- Catalog number:
- DL-ADRb3-Mu
- Product Quantity:
- 96T
- Category:
- Elisa Kits
- Supplier:
- WDSTD
- Gene target:
- ADRb3 ELISA kit
Related genes to: ADRb3 ELISA kit
- Gene:
- ADRB3 NIH gene
- Name:
- adrenoceptor beta 3
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 8p11.23
- Locus Type:
- gene with protein product
- Date approved:
- 1993-10-04
- Date modifiied:
- 2015-10-15
Related products to: ADRb3 ELISA kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: ADRb3 ELISA kit
- Sulfur amino acid restriction (SAAR) paradoxically increases food intake while inducing weight loss, but the mechanisms underlying these outcomes remain unclear. To investigate the role of leptin in this response, we assessed food intake, body weight, and metabolic markers in diet-induced obese (DIO), leptin-deficient (ob/ob), and leptin receptor-deficient (db/db) mice. In DIO-SAAR mice, increased food intake was associated with hypothalamic upregulation of orexigenic (Agrp, Npy, and Mchr1) and downregulation of anorexigenic (Pomc, Cartpt, and Bdnf) mRNA levels. This orexigenic profile is accompanied by reduced adiposity and lower circulating leptin levels, suggesting that decreased leptin may induce compensatory increased food intake. Despite increased food intake, SAAR also induces weight loss, which is associated with enhanced β3-adrenergic signaling in brown and inguinal white AT (BAT and iWAT), as reflected by elevated Adrb3 and Ucp1 mRNA levels but downregulated protein expression, suggesting post-transcriptional regulation. These phenotypes induced by SAAR may possibly involve thyroid hormone metabolism, as indicated by increased circulating T3 and T4 concentrations and upregulation of BAT deiodinase 2 (D2) mRNA. Importantly, these metabolic effects of SAAR are attenuated in ob/ob and abolished in db/db mice, despite reductions in circulating SAA levels. Furthermore, leptin treatment during SAAR reduced food intake, induced weight loss, demonstrating preserved leptin sensitivity in low fat diet-fed and ob/ob mice. These findings reveal that leptin is required for both increased food intake and weight loss during SAAR. - Source: PubMed
Publication date: 2026/05/05
Cooke DianaOuattara AmadouAbles Gene P - Obesity remains a global health challenge, and promoting white adipose tissue browning has emerged as a promising anti-obesity strategy. This study aimed to investigate the anti-obesity effects of denatonium benzoate (DB) and elucidate its underlying mechanisms. - Source: PubMed
Publication date: 2026/04/02
Niu YiqinShao JunhuiTeng YanpingZhang CeXie XinGuo Shimeng - Recent studies have shown that from the 23rd week of gestation onward, the fetus becomes progressively more hypoxic, with oxygenation levels rising again after 33-34 weeks. The biological significance of this biphasic oxygenation pattern has remained unclear. - Source: PubMed
Publication date: 2026/04/03
Scaramuzzo Rosa TeresaFilippini LucreziaCalvani MauraTirinnanzi BiancaCrucitta StefaniaDel Re MarziaMorganti RiccardoDi Marsico LorenzaCammalleri MaurizioBagnoli PaolaDal Monte MassimoPini AlessandroFilippi Luca - - Source: PubMed
Publication date: 2026/03/31
Diani Luísa MariaWatanabe Lígia MoriguchiNoronha Natália Yumida Silva Rodrigues Guilhermede Souza Pinhel Marcela AugustaSae-Lee Chanachaide Oliveira Bruno Affonso ParentiNicoletti Carolina FerreiraJunqueira Gizela PedrosoSalgado WilsonMarchini Júlio SérgioNonino Carla Barbosa - Dihydroquercetin (DHQ) is a promising object for the development of a treatment for patients with obesity and prediabetes requiring a moderate therapeutic effect. This paper reports a clinical case of DHQ application in a 30-year-old Caucasian male and proposes a molecular mechanism of its anti-obesity effect. DHQ was administrated as a dietary supplement at a dose of 100-200 mg/day during 3 months with treatment interruption for 1 month. The data collected one month before the treatment were used as a control. The molecular aspects were studied via molecular docking with β-adrenoceptor (ADRB3, PDB ID: 9IJE) and peroxisome proliferator-activated receptor γ (PPARG, PDB ID: 2ZNO) and molecular dynamic simulation under conditions mimicking a human cellular environment. A pronounced weight decrease up to 0.73 kg/week was observed during DHQ administration. The highest affinity to ADRB3 was observed for the non-ionized H2H3-conformation of 2,3-DHQ (-8.846 kcal/mol). Molecules with 2-configuration demonstrate 0.332 kcal/mol higher affinity to PPARG compared to 2-stereoisomers. The intermolecular complex with -DHQ demonstrated higher stability in molecular dynamics simulation. The insights gained from this study may contribute to our understanding of flavonoids not merely as antioxidants but also as active ingredients that selectively interact with receptors. If future investigations confirm these results, they may serve as a foundation for developing a new class of anti-obesity remedies that act via ADRB3. - Source: PubMed
Publication date: 2026/03/20
Terekhov Roman PTaldaev AmirSvotin Artem APankov Denis ISukhova Evgenia MManukov David ABergel KetelinaKorochkina Maria DSelivanova Irina A